Financial News
Articles published by Natera, Inc.
Court Grants Natera’s Request to Include Additional Patent in its Lawsuit Against NeoGenomics
December 17, 2024
From Natera, Inc.
Via Business Wire
Tickers
NTRA
Natera Announces Enrollment of First Patients in SAGITTARIUS: a Randomized, Phase III Clinical Trial in Colon Cancer
December 12, 2024
From Natera, Inc.
Via Business Wire
Tickers
NTRA
Clinical Validation Study on Natera’s Fetal RhD NIPT Published in Obstetrics & Gynecology
December 02, 2024
From Natera, Inc.
Via Business Wire
Tickers
NTRA
Natera Announces Medicare Coverage for Prospera™ in Single Lung Transplant Recipients
November 27, 2024
From Natera, Inc.
Via Business Wire
Tickers
NTRA
Natera to Present New SignateraTM Data in Multiple Abstracts at the San Antonio Breast Cancer Symposium
November 25, 2024
From Natera, Inc.
Via Business Wire
Tickers
NTRA
Natera Issues Statement on Guardant Health Litigation
November 25, 2024
From Natera, Inc.
Via Business Wire
Tickers
NTRA
Natera Co-Founder and Executive Chairman Matthew Rabinowitz Named 2024 R&D Leader of the Year
November 25, 2024
From Natera, Inc.
Via Business Wire
Tickers
NTRA
Natera Reports Third Quarter 2024 Financial Results
November 12, 2024
From Natera, Inc.
Via Business Wire
Tickers
NTRA
Natera to Participate in Upcoming Investor Conferences
November 08, 2024
From Natera, Inc.
Via Business Wire
Tickers
NTRA
Natera to Report its Third Quarter 2024 Results on November 12, 2024
November 01, 2024
From Natera, Inc.
Via Business Wire
Tickers
NTRA
Natera to Present New Renasight Data at ASN Kidney Week 2024
October 22, 2024
From Natera, Inc.
Via Business Wire
Tickers
NTRA
Court Orders Permanent Injunction Against NeoGenomics' Accused RaDaR Assay, as Case Enters New Phase
September 23, 2024
From Natera, Inc.
Via Business Wire
Tickers
NTRA
Natera to Present New Signatera™ Colorectal Cancer Data at ESMO Showing 10X Advantage in Overall Survival
September 08, 2024
From Natera, Inc.
Via Business Wire
Tickers
NTRA
Natera Reports Second Quarter 2024 Financial Results
August 08, 2024
From Natera, Inc.
Via Business Wire
Tickers
NTRA
New MultiCenter Prospective Study Demonstrates Signatera’s Clinical Utility in Merkel Cell Carcinoma
July 26, 2024
From Natera, Inc.
Via Business Wire
Tickers
NTRA
Natera to Present at the 28th International Conference on Prenatal Diagnosis and Therapy
July 03, 2024
From Natera, Inc.
Via Business Wire
Tickers
NTRA
Natera Announces DECIPHER: A Phase II, Single-Arm Adjuvant Trial in Gastroesophageal Cancer
June 27, 2024
From Natera, Inc.
Via Business Wire
Tickers
NTRA
Natera Presents Latest in Transplant Innovation Data Across Multiple Organs at ATC 2024
May 30, 2024
From Natera, Inc.
Via Business Wire
Tickers
NTRA
Natera Announces New MRD Data in Multiple Tumor Types, to be Presented at ASCO Annual Meeting
May 23, 2024
From Natera, Inc.
Via Business Wire
Tickers
NTRA
Natera Reports First Quarter 2024 Financial Results
May 09, 2024
From Natera, Inc.
Via Business Wire
Tickers
NTRA
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.